U.S., March 29 -- ClinicalTrials.gov registry received information related to the study (NCT06899828) titled 'Unraveling Mechanism of Action of Extracorporeal Photopheresis in Heart and Lung Transplant Patients' on March 21.
Brief Summary: This is a prospective observational single center national study. Lung and heart transplant patients with a definite diagnosis of chronic lung allograft dysfunction (CLAD) or cardiac allograft vasculopathy (CAV) will be assigned for extracorporeal photopheresis (ECP) as per common clinical practice to a 6-month ECP cycle with the aim of limiting progression of organ dysfunction. The exact mechanisms of ECP in chronic rejection after lung and heart transplantation (CLAD and CAV) are elusive but it is thou...